Phase III Evaluation of Asundexian in Non-Cardioembolic Stroke and TIA

Article Impact Level: HIGH
Data Quality: STRONG
Summary of  New England Journal of Medicine https://doi.org/10.1056/NEJMoa2513880
Dr. Jaime Masjuan et al.

Points

Investigators conducted a large international phase III trial involving over twelve thousand participants to evaluate if adding asundexian to standard antiplatelet therapy could safely prevent recurrent ischemic strokes.
Results showed that asundexian reduced the occurrence of subsequent ischemic strokes by twenty-six percent compared to a placebo while maintaining an exceptionally favorable safety profile for all participants.
Clinical data indicated a seventeen percent reduction in major cardiovascular events and a thirty-one percent decrease in the incidence of disabling or fatal strokes among those taking the medication.
The novel drug works by inhibiting Factor XIa which prevents the formation of harmful blood clots while allowing the body to maintain its natural and necessary bleeding control mechanisms.
These findings provide a high level of hope for a safer alternative to current anti-clotting drugs that frequently cause dangerous bleeding when used for long-term secondary stroke prevention.

Summary

This study evaluated the safety and efficacy of asundexian, an investigational Factor XIa inhibitor, for the secondary prevention of ischemic stroke. In the phase III OCEANIC-STROKE trial, 12,327 adults from 37 countries were enrolled within 72 hours of a non-cardioembolic stroke or high-risk TIA. Given that traditional antiplatelet therapies offer only modest protection and carry significant hemorrhage risks, the research sought to determine if inhibiting Factor XIa could reduce recurrent thrombotic events without compromising primary hemostasis.

Analysis of the data demonstrated that asundexian (50 mg daily) significantly improved clinical outcomes when added to standard antiplatelet therapy. Recurrent ischemic stroke occurred in 6.2% of the asundexian group compared to 8.4% in the placebo group, representing a 26% relative risk reduction. Major cardiovascular events (stroke, myocardial infarction, or cardiovascular death) were reduced by 17% (9.2% vs. 11.1%), and disabling or fatal strokes saw a 31% reduction (2.1% vs. 3.0%). Critically, despite the enhanced antithrombotic effect, there was no observed increase in the incidence of major bleeding compared to placebo.

The findings suggest that asundexian provides a safer paradigm for long-term secondary stroke prevention by selectively targeting the intrinsic coagulation pathway. By blocking Factor XIa, the medication prevents pathologic thrombus formation while preserving the body’s natural ability to stop bleeding at sites of vascular injury. This trial marks the first successful large-scale validation of Factor XIa inhibition in this patient population. Future clinical implementation remains contingent on ongoing regulatory review, but these results offer a high-probability roadmap for reducing the global burden of recurrent ischemic stroke.

Link to the article: https://www.nejm.org/doi/10.1056/NEJMoa2513880

References

Sharma, M., Dong, Q., Hirano, T., Kasner, S. E., Saver, J. L., Masjuan, J., Demchuk, A. M., Cordonnier, C., Bereczki, D., Tsivgoulis, G., Veltkamp, R., Staikov, I., Bae, H.-J., Campbell, B. C. V., Zini, A., Lee, I.-H., Kovar, M., Mikulik, R., Lemmens, R., … Shoamanesh, A. (2026). Asundexian for secondary stroke prevention. New England Journal of Medicine, 394(15), 1467–1479. https://doi.org/10.1056/NEJMoa2513880